1. PHTALOX® Mouthwash as An Option to Reduce Clinical Symptoms of COVID-19: Case Series
- Author
-
Paulo Sérgio da Silva Santos, Lucas Marques da Costa Alves, Fabiano Vieira Vilhena, Rodrigo Cardoso de Oliveira, Mariana Schützer Ragghianti Zangrando, Bernardo da Fonseca Orcina, Koiti Araki, and Sérgio Hiroshi Toma
- Subjects
medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,Performance status ,business.industry ,body regions ,Clinical trial ,Measurement scales ,stomatognathic system ,Internal medicine ,medicine ,Sore throat ,Gargling ,medicine.symptom ,Mouth ulcers ,business ,Viral load - Abstract
Background: The PHTALOX® mouthwash appears in this case series as a promising alternative for reducing the viral load of SARS-CoV-2 and for clinical improvement of infected patients. Objectives: The aim of this study was to report a case series of mouthwash to reduce clinical symptoms in patients diagnosed with COVID-19. Methods: Eight patients used 5ml of PHTALOX® mouthwash for gargling/rinsing during 1 minute/ five times a day during 14 days. Two measurement scales were applied for each patient in different periods to verify sore throat - VAS – Visual Analogic Scale for Pain and the clinical conditions - PS – Performance Status. Results: All patients presented a significant reduction in clinical symptoms with PHTALOX® mouthwash for gargling/rinsing after few days of use, without hospitalization. Conclusion: The PHTALOX® mouthwash protocol appears as a promising alternative for clinical improvement of COVID-19 infected patients. Daily use of this mouthwash rapidly reduced clinical symptoms such as sore throats, coughs and mouth ulcers. Clinical trials are necessary to confirm the effectiveness of PHTALOX® protocol against COVID-19.
- Published
- 2020
- Full Text
- View/download PDF